Effect of Long-Term Hydroxytyrosol Administration on Body Weight, Fat Mass and Urine Metabolomics: A Randomized Double-Blind Prospective Human Study

Nutrients

Charilaos Dimosthenopoulos¹  Alexios L. Skaltsounis²  Maria Halabalaki²  Theodora Nikou²  Dimitrios Simos³  Christina Fytili³  Petros P. Sfikakis³  Alexandros Kokkinos³  Nikolaos Tentolouris³  Nikolaos Katsilambros⁴  Ioulia K. Tseti⁵ 

[1] Department of Clinical Nutrition, Laiko General Hospital, 17 Agiou Thoma Street, 11527 Athens, Greece;Department of Pharmacy, Division of Pharmacognosy and Natural Products Chemistry, National and Kapodistrian University of Athens, Panepistimioupoli Zografou, 11527 Athens, Greece;First Department of Propaedeutic and Internal Medicine, Medical School, National and Kapodistrian University of Athens, Laiko General Hospital, 17 Agiou Thoma Street, 11527 Athens, Greece;Research Laboratory Christeas Hall, Medical School, National and Kapodistrian University of Athens, 15b Agiou Thoma Street, 11527 Athens, Greece;Uni-Pharma SA, 14th klm National Road 1, Kifissia, 14564 Athens, Greece;

关键词: hydroxytyrosol;    human cohort;    obesity;    weight and fat loss;    UPLC-Orbitrap-MS;    metabolomics;   

DOI  :  10.3390/nu14071525

来源: DOAJ

【 摘 要 】

Hydroxytyrosol (HT) is a natural antioxidant found in olive products and characterized by well-documented beneficial effects on human health. Several research studies are ongoing that aim to investigate its potency and molecular mechanism of action. The present study aimed to investigate the potential effect of HT on human obesity through a randomized double-blind prospective design. HT in two different doses (15 and 5 mg/day) and a placebo capsule was administered to 29 women with overweight/obesity for six months and their weight and fat mass were monitored at three time points (baseline, 4, 12 and 24 weeks). Statistically significant weight and visceral fat mass loss (%weight loss: p = 0.012, %visceral fat loss: p = 0.006) were observed in the group receiving the maximum HT dosage versus placebo after 4 weeks of the intervention, with attenuation of these findings at 12 and 24 weeks of the study. Urine samples were collected during the intervention and analyzed via liquid chromatography–high-resolution mass spectrometry for untargeted metabolomic purposes and comparisons between study groups were performed. HT administration was safe and well-tolerated. To the best of our knowledge, this is the first human cohort investigating the effects of HT on obesity for a prolonged study period.

【 授权许可】

Unknown